FDA Brief

Warning letters Drugs

FDA warning letter to

USV Private Limited

High riskIssued Nov 2Posted Nov 10Center for Drug Evaluation and Research (CDER)

FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

What happened

FDA inspected USV's drug manufacturing facility in Dabhel, Daman, India, from April 7 to 17, 2026. The agency found aseptic processing and facility/equipment design problems that risked contamination of sterile injectables, plus an inadequate visual inspection program for visible particulates. FDA reviewed USV's May 8, 2026, response to the Form FDA 483 (inspection observations) and found it inadequate.

What FDA found

  1. USV lacked adequate aseptic-processing procedures and controls; smoke studies showed swirling or upward airflow rather than unidirectional flow, and operators breached first air during interventions, risking sterility.

    21 CFR 211.113(b)
  2. The facility and equipment design did not adequately protect sterile drugs; a conveyor blocked ISO 5 airflow and critical aseptic areas could not maintain ISO 5 conditions.

    21 CFR 211.42(c) and 21 CFR 211.63
  3. USV's visual inspection program for injectables lacked action limits for visible particulates, did not classify particles as extrinsic or intrinsic, and failed to investigate atypical trends.

    21 CFR 211.160(b)
  4. USV released some batches without adequate visible-particulate assessment before March 28, 2026.

    21 CFR 211.160(b)
  5. FDA found USV's quality systems inadequate and said the quality unit was not enabled to exercise proper authority or had not sufficiently implemented its responsibilities.

What FDA wants

FDA asks USV to promptly address the violations and provide comprehensive CAPA plans, independent risk assessments and airflow/visual-inspection remediation, plus a qualified consultant's six-system audit before seeking resolution of its compliance status. It also asks USV to clarify whether it will resume U.S. manufacturing and to notify FDA before resuming; no response deadline is stated in the letter.

Who should pay attention

  • Sterile injectable manufacturers and aseptic fill-finish operations
  • Companies buying or distributing USV's sterile injectables
  • Quality teams responsible for visual inspection and contamination control

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  2. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  3. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk
  4. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk